Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial
Marcello Tiseo(University of Parma), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Francesca Zanelli(Ospedale Santa Maria), Gianni Michele Turolla(Azienda Ospedaliero-Universitaria Careggi), Francesco Grossi(University of Insubria), Anna Rita Trolese(Azienda Ospedaliero-Universitaria Careggi), Efisio Defraia, E Baldini, Nicoletta Zilembo(ANT Foundation Italy Onlus), M. Brighenti, Andrea Camerini(Ospedale Versilia), Carmelo Tibaldi(Azienda Ospedaliero-Universitaria Careggi), Luca Boni(Ospedale Policlinico San Martino), Claudio Dazzi(Azienda Ospedaliero-Universitaria Careggi), Vito D’Alessandro(Azienda Ospedaliero-Universitaria Careggi), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Francesca Ambrosio(Azienda Ospedaliero-Universitaria Careggi), Saverio Cinieri(Ospedale A. Perrino)
Cited by 2
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k